PatientView is a UK-based research, publishing, and consultancy group, created out of a belief that the views of patients should be considered in all important healthcare decisions (whether a new healthcare product is being developed, or whether a government is instituting changes to a health system).
The recently published 2023 Global report, covering the period November 2023 to late-February 2024 contains views on pharma/patient-group relations invited by PatientView from a number of pharmaceutical companies (or company divisions): Bayer AG; Boehringer Ingelheim; Gilead Sciences; Novartis; Novo Nordisk (Obesity Division); Pfizer; Pfizer (Immunology and Inflammation Division); and ViiV Healthcare. The report is based on the results of a survey of 2,518 patient groups from 106 countries.
A patient summary is available at this link and can be downloaded below.
We have pulled out three key points from the patient summary:
1. The proportion of patient groups considering the corporate reputation of the pharma industry to be either “Excellent” or “Good” has risen markedly over recent years (from 33% in 2014, to 57% in 2023), but the beneficial reputational impact of a ‘Covid-19 boost’ might perhaps be wearing off.
2. 53% of 2023’s respondent patient groups described the pharma industry as “Excellent” or “Good” at patient-group relations. The nature of company/patient-group relationships is maturing. Of course, there are also areas in which pharma companies continue to fall short, even after ten years.
3. The majority of the patient groups responding to the survey think that three areas of improvement are needed from the pharma industry:
- Drug pricing
- Medication availability
- Patient involvement in Research and Development